We are analyzing https://link.springer.com/article/10.1007/s11523-022-00942-6.

Title:
Optimizing Patient Pathways in Advanced Biliary Tract Cancers: Recent Advances and a French Perspective | Targeted Oncology
Description:
Biliary tract cancers (BTCs) are a heterogeneous group of tumors that are rare in Western countries and have a poor prognosis. Three subgroups are defined by their anatomical location (intrahepatic cholangiocarcinoma, extrahepatic cholangiocarcinoma and gallbladder carcinoma) and exhibit distinct clinical, molecular, and epidemiologic characteristics. Most patients are diagnosed at an advanced disease stage and are not eligible for curative-intent resection. In addition to first- and second-line chemotherapies (CisGem and FOLFOX, respectively), biologic therapies are now available that target specific genomic alterations identified in BTC. To date, targets include alterations in the genes for isocitrate dehydrogenase (IDH) 1, fibroblast growth factor receptor (FGFR) 2, v-raf murine sarcoma viral oncogene homolog B1 (BRAF), human epidermal growth factor receptor 2 (HER2 or ERRB2), and neurotrophic tyrosine receptor kinase (NTRK), and for those leading to DNA mismatch repair deficiency. Therapies targeting these genomic alterations have demonstrated clinical benefit for patients with BTC. Despite these therapeutic advancements, genomic diagnostic modalities are not widely used in France, owing to a lack of clinician awareness, local availability of routine genomic testing, and difficulties in obtaining health insurance reimbursement. The addition of durvalumab, a monoclonal antibody targeting the immune checkpoint programmed cell death ligand-1, to CisGem in the first-line treatment of advanced BTC has shown an overall survival benefit in the TOPAZ-1 trial. Given the high mortality rates associated with BTC and the life-prolonging therapeutic options now available, it is hoped that the data presented here will support updates to the clinical management of BTC in France.
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {📚}

Education
Health & Fitness
Science

Content Management System {📝}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month

Based on our best estimate, this website will receive around 7,626,432 visitors per month in the current month.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

The income method remains a mystery to us.

Some websites aren't about earning revenue; they're built to connect communities or raise awareness. There are numerous motivations behind creating websites. This might be one of them. Link.springer.com could be secretly minting cash, but we can't detect the process.

Keywords {🔍}

patients, pubmed, article, google, scholar, cancer, cas, biliary, study, btc, phase, advanced, tract, cholangiocarcinoma, oncol, central, icca, trial, months, idh, treatment, fgfr, gemcitabine, clinical, median, chemotherapy, alterations, france, mutations, therapy, cisgem, cancers, therapies, genomic, group, cca, table, intrahepatic, disease, results, randomized, esmo, clin, french, tumor, response, firstline, httpsdoiorgs, targeted, molecular,

Topics {✒️}

fr/upload/docs/evamed/cnedimts-6082_therasphere_28_janvier_2020_ braf proto-oncogene b-raf patients receiving nal-iri-5-fu-lv nanoparticle albumin-bound–paclitaxel provided receiving nal-iri-5-fu-lv article google scholar mitogen-activated protein kinase nal-iri-5-fu-lv arm nal-iri-5-fu-lv regimen agents targeting pd-1/pd-l1 advanced biliary-tract cancer formalin-fixed paraffin-embedded bispecific her2-targeted antibody anti-pd-1 monoclonal antibody ntrk fusion-positive cancers nal-iri-5-fu-lv adenocarcinoma/large duct type adenocarcinoma/small duct type atm ataxia-telangiectasia mutated jean-christophe sabourin ntrk gene fusion-positive trk fusion–positive cancers gov/drugsatfda_docs/label/2020/021492s016lbl gov/drugsatfda_docs/label/2021/211710s004lbl gov/drugsatfda_docs/label/2021/125514s096lbl gov/drugsatfda_docs/label/2021/211192_s008lbl gov/drugsatfda_docs/label/2019/212725s000lbl gov/drugsatfda_docs/label/2020/213736s000lbl gov/drugsatfda_docs/label/2021/214622s000lbl gov/drugsatfda_docs/label/2022/214801s000lbl trans-arterial embolisation therapies abou-alfa gk monoclonal antibody targeting université de paris population-based case-control study anti–pd-l1 antibody article download pdf curative-intent secondary resection antibody-drug conjugate consisting biliary tract cancers tyrosine kinase receptors paraffin-embedded tumor samples optimizing patient pathways dual anti-her2 regimen post-baseline tumor measurements mgmt methylguanine-dna methyltransferase broad-based tumor genotyping common bile duct durable anti-tumor activity actual long-term outcome

Questions {❓}

Is MGMT methylation a new therapeutic target for biliary tract cancer?
Oxaliplatin and ototoxicity: is it really safe for hearing?
Radiation therapy for liver tumors: ready for inclusion in guidelines?

Schema {🗺️}

WebPage:
      mainEntity:
         headline:Optimizing Patient Pathways in Advanced Biliary Tract Cancers: Recent Advances and a French Perspective
         description:Biliary tract cancers (BTCs) are a heterogeneous group of tumors that are rare in Western countries and have a poor prognosis. Three subgroups are defined by their anatomical location (intrahepatic cholangiocarcinoma, extrahepatic cholangiocarcinoma and gallbladder carcinoma) and exhibit distinct clinical, molecular, and epidemiologic characteristics. Most patients are diagnosed at an advanced disease stage and are not eligible for curative-intent resection. In addition to first- and second-line chemotherapies (CisGem and FOLFOX, respectively), biologic therapies are now available that target specific genomic alterations identified in BTC. To date, targets include alterations in the genes for isocitrate dehydrogenase (IDH) 1, fibroblast growth factor receptor (FGFR) 2, v-raf murine sarcoma viral oncogene homolog B1 (BRAF), human epidermal growth factor receptor 2 (HER2 or ERRB2), and neurotrophic tyrosine receptor kinase (NTRK), and for those leading to DNA mismatch repair deficiency. Therapies targeting these genomic alterations have demonstrated clinical benefit for patients with BTC. Despite these therapeutic advancements, genomic diagnostic modalities are not widely used in France, owing to a lack of clinician awareness, local availability of routine genomic testing, and difficulties in obtaining health insurance reimbursement. The addition of durvalumab, a monoclonal antibody targeting the immune checkpoint programmed cell death ligand-1, to CisGem in the first-line treatment of advanced BTC has shown an overall survival benefit in the TOPAZ-1 trial. Given the high mortality rates associated with BTC and the life-prolonging therapeutic options now available, it is hoped that the data presented here will support updates to the clinical management of BTC in France.
         datePublished:2023-02-06T00:00:00Z
         dateModified:2023-02-06T00:00:00Z
         pageStart:51
         pageEnd:76
         license:http://creativecommons.org/licenses/by-nc/4.0/
         sameAs:https://doi.org/10.1007/s11523-022-00942-6
         keywords:
            Oncology
            Biomedicine
            general
         image:
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs11523-022-00942-6/MediaObjects/11523_2022_942_Fig1_HTML.png
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs11523-022-00942-6/MediaObjects/11523_2022_942_Fig2_HTML.png
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs11523-022-00942-6/MediaObjects/11523_2022_942_Fig3_HTML.png
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs11523-022-00942-6/MediaObjects/11523_2022_942_Fig4_HTML.png
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs11523-022-00942-6/MediaObjects/11523_2022_942_Fig5_HTML.png
         isPartOf:
            name:Targeted Oncology
            issn:
               1776-260X
               1776-2596
            volumeNumber:18
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Springer International Publishing
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Cindy Neuzillet
               affiliation:
                     name:Institut Curie
                     address:
                        name:Institut Curie, St Cloud, France
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Pascal Artru
               affiliation:
                     name:Jean Mermoz Hospital
                     address:
                        name:Jean Mermoz Hospital, Lyon, France
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Eric Assenat
               affiliation:
                     name:CHU Montpellier
                     address:
                        name:CHU Montpellier, Montpellier, France
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Julien Edeline
               url:http://orcid.org/0000-0002-8289-7741
               affiliation:
                     name:Centre Eugène Marquis
                     address:
                        name:Centre Eugène Marquis, Rennes, France
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Xavier Adhoute
               affiliation:
                     name:Saint Joseph Hospital
                     address:
                        name:Saint Joseph Hospital, Marseille, France
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Jean-Christophe Sabourin
               affiliation:
                     name:Rouen University Hospital, Normandie University
                     address:
                        name:Department of Pathology, Rouen University Hospital, Normandie University, Rouen, France
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Anthony Turpin
               url:http://orcid.org/0000-0002-2282-0101
               affiliation:
                     name:Lille University Hospital
                     address:
                        name:Lille University Hospital, Lille, France
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Romain Coriat
               affiliation:
                     name:CHU Cochin, Service de Gastroentérologie, Hôpital Cochin, Université de Paris
                     address:
                        name:CHU Cochin, Service de Gastroentérologie, Hôpital Cochin, Université de Paris, Paris, France
                        type:PostalAddress
                     type:Organization
               type:Person
               name:David Malka
               url:http://orcid.org/0000-0002-7664-0130
               affiliation:
                     name:Institut Mutualiste Montsouris
                     address:
                        name:Department of Medical Oncology, Institut Mutualiste Montsouris, Paris Cedex 14, France
                        type:PostalAddress
                     type:Organization
                     name:Université Paris-Saclay
                     address:
                        name:Université Paris-Saclay, Villejuif, France
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
         isAccessibleForFree:1
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:Optimizing Patient Pathways in Advanced Biliary Tract Cancers: Recent Advances and a French Perspective
      description:Biliary tract cancers (BTCs) are a heterogeneous group of tumors that are rare in Western countries and have a poor prognosis. Three subgroups are defined by their anatomical location (intrahepatic cholangiocarcinoma, extrahepatic cholangiocarcinoma and gallbladder carcinoma) and exhibit distinct clinical, molecular, and epidemiologic characteristics. Most patients are diagnosed at an advanced disease stage and are not eligible for curative-intent resection. In addition to first- and second-line chemotherapies (CisGem and FOLFOX, respectively), biologic therapies are now available that target specific genomic alterations identified in BTC. To date, targets include alterations in the genes for isocitrate dehydrogenase (IDH) 1, fibroblast growth factor receptor (FGFR) 2, v-raf murine sarcoma viral oncogene homolog B1 (BRAF), human epidermal growth factor receptor 2 (HER2 or ERRB2), and neurotrophic tyrosine receptor kinase (NTRK), and for those leading to DNA mismatch repair deficiency. Therapies targeting these genomic alterations have demonstrated clinical benefit for patients with BTC. Despite these therapeutic advancements, genomic diagnostic modalities are not widely used in France, owing to a lack of clinician awareness, local availability of routine genomic testing, and difficulties in obtaining health insurance reimbursement. The addition of durvalumab, a monoclonal antibody targeting the immune checkpoint programmed cell death ligand-1, to CisGem in the first-line treatment of advanced BTC has shown an overall survival benefit in the TOPAZ-1 trial. Given the high mortality rates associated with BTC and the life-prolonging therapeutic options now available, it is hoped that the data presented here will support updates to the clinical management of BTC in France.
      datePublished:2023-02-06T00:00:00Z
      dateModified:2023-02-06T00:00:00Z
      pageStart:51
      pageEnd:76
      license:http://creativecommons.org/licenses/by-nc/4.0/
      sameAs:https://doi.org/10.1007/s11523-022-00942-6
      keywords:
         Oncology
         Biomedicine
         general
      image:
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs11523-022-00942-6/MediaObjects/11523_2022_942_Fig1_HTML.png
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs11523-022-00942-6/MediaObjects/11523_2022_942_Fig2_HTML.png
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs11523-022-00942-6/MediaObjects/11523_2022_942_Fig3_HTML.png
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs11523-022-00942-6/MediaObjects/11523_2022_942_Fig4_HTML.png
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs11523-022-00942-6/MediaObjects/11523_2022_942_Fig5_HTML.png
      isPartOf:
         name:Targeted Oncology
         issn:
            1776-260X
            1776-2596
         volumeNumber:18
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Springer International Publishing
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Cindy Neuzillet
            affiliation:
                  name:Institut Curie
                  address:
                     name:Institut Curie, St Cloud, France
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Pascal Artru
            affiliation:
                  name:Jean Mermoz Hospital
                  address:
                     name:Jean Mermoz Hospital, Lyon, France
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Eric Assenat
            affiliation:
                  name:CHU Montpellier
                  address:
                     name:CHU Montpellier, Montpellier, France
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Julien Edeline
            url:http://orcid.org/0000-0002-8289-7741
            affiliation:
                  name:Centre Eugène Marquis
                  address:
                     name:Centre Eugène Marquis, Rennes, France
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Xavier Adhoute
            affiliation:
                  name:Saint Joseph Hospital
                  address:
                     name:Saint Joseph Hospital, Marseille, France
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Jean-Christophe Sabourin
            affiliation:
                  name:Rouen University Hospital, Normandie University
                  address:
                     name:Department of Pathology, Rouen University Hospital, Normandie University, Rouen, France
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Anthony Turpin
            url:http://orcid.org/0000-0002-2282-0101
            affiliation:
                  name:Lille University Hospital
                  address:
                     name:Lille University Hospital, Lille, France
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Romain Coriat
            affiliation:
                  name:CHU Cochin, Service de Gastroentérologie, Hôpital Cochin, Université de Paris
                  address:
                     name:CHU Cochin, Service de Gastroentérologie, Hôpital Cochin, Université de Paris, Paris, France
                     type:PostalAddress
                  type:Organization
            type:Person
            name:David Malka
            url:http://orcid.org/0000-0002-7664-0130
            affiliation:
                  name:Institut Mutualiste Montsouris
                  address:
                     name:Department of Medical Oncology, Institut Mutualiste Montsouris, Paris Cedex 14, France
                     type:PostalAddress
                  type:Organization
                  name:Université Paris-Saclay
                  address:
                     name:Université Paris-Saclay, Villejuif, France
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
      isAccessibleForFree:1
["Periodical","PublicationVolume"]:
      name:Targeted Oncology
      issn:
         1776-260X
         1776-2596
      volumeNumber:18
Organization:
      name:Springer International Publishing
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:Institut Curie
      address:
         name:Institut Curie, St Cloud, France
         type:PostalAddress
      name:Jean Mermoz Hospital
      address:
         name:Jean Mermoz Hospital, Lyon, France
         type:PostalAddress
      name:CHU Montpellier
      address:
         name:CHU Montpellier, Montpellier, France
         type:PostalAddress
      name:Centre Eugène Marquis
      address:
         name:Centre Eugène Marquis, Rennes, France
         type:PostalAddress
      name:Saint Joseph Hospital
      address:
         name:Saint Joseph Hospital, Marseille, France
         type:PostalAddress
      name:Rouen University Hospital, Normandie University
      address:
         name:Department of Pathology, Rouen University Hospital, Normandie University, Rouen, France
         type:PostalAddress
      name:Lille University Hospital
      address:
         name:Lille University Hospital, Lille, France
         type:PostalAddress
      name:CHU Cochin, Service de Gastroentérologie, Hôpital Cochin, Université de Paris
      address:
         name:CHU Cochin, Service de Gastroentérologie, Hôpital Cochin, Université de Paris, Paris, France
         type:PostalAddress
      name:Institut Mutualiste Montsouris
      address:
         name:Department of Medical Oncology, Institut Mutualiste Montsouris, Paris Cedex 14, France
         type:PostalAddress
      name:Université Paris-Saclay
      address:
         name:Université Paris-Saclay, Villejuif, France
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Cindy Neuzillet
      affiliation:
            name:Institut Curie
            address:
               name:Institut Curie, St Cloud, France
               type:PostalAddress
            type:Organization
      name:Pascal Artru
      affiliation:
            name:Jean Mermoz Hospital
            address:
               name:Jean Mermoz Hospital, Lyon, France
               type:PostalAddress
            type:Organization
      name:Eric Assenat
      affiliation:
            name:CHU Montpellier
            address:
               name:CHU Montpellier, Montpellier, France
               type:PostalAddress
            type:Organization
      name:Julien Edeline
      url:http://orcid.org/0000-0002-8289-7741
      affiliation:
            name:Centre Eugène Marquis
            address:
               name:Centre Eugène Marquis, Rennes, France
               type:PostalAddress
            type:Organization
      name:Xavier Adhoute
      affiliation:
            name:Saint Joseph Hospital
            address:
               name:Saint Joseph Hospital, Marseille, France
               type:PostalAddress
            type:Organization
      name:Jean-Christophe Sabourin
      affiliation:
            name:Rouen University Hospital, Normandie University
            address:
               name:Department of Pathology, Rouen University Hospital, Normandie University, Rouen, France
               type:PostalAddress
            type:Organization
      name:Anthony Turpin
      url:http://orcid.org/0000-0002-2282-0101
      affiliation:
            name:Lille University Hospital
            address:
               name:Lille University Hospital, Lille, France
               type:PostalAddress
            type:Organization
      name:Romain Coriat
      affiliation:
            name:CHU Cochin, Service de Gastroentérologie, Hôpital Cochin, Université de Paris
            address:
               name:CHU Cochin, Service de Gastroentérologie, Hôpital Cochin, Université de Paris, Paris, France
               type:PostalAddress
            type:Organization
      name:David Malka
      url:http://orcid.org/0000-0002-7664-0130
      affiliation:
            name:Institut Mutualiste Montsouris
            address:
               name:Department of Medical Oncology, Institut Mutualiste Montsouris, Paris Cedex 14, France
               type:PostalAddress
            type:Organization
            name:Université Paris-Saclay
            address:
               name:Université Paris-Saclay, Villejuif, France
               type:PostalAddress
            type:Organization
      email:[email protected]
PostalAddress:
      name:Institut Curie, St Cloud, France
      name:Jean Mermoz Hospital, Lyon, France
      name:CHU Montpellier, Montpellier, France
      name:Centre Eugène Marquis, Rennes, France
      name:Saint Joseph Hospital, Marseille, France
      name:Department of Pathology, Rouen University Hospital, Normandie University, Rouen, France
      name:Lille University Hospital, Lille, France
      name:CHU Cochin, Service de Gastroentérologie, Hôpital Cochin, Université de Paris, Paris, France
      name:Department of Medical Oncology, Institut Mutualiste Montsouris, Paris Cedex 14, France
      name:Université Paris-Saclay, Villejuif, France

External Links {🔗}(709)

Analytics and Tracking {📊}

Google Tag Manager

Libraries {📚}

Clipboard.js
Prism.js

CDN Services {📦}

Crossref

5.41s.

LINK . SPRINGER . COM {}